These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 8742313)

  • 1. Variability in gene expression and tumor formation within genetically homogeneous animal populations in bioassays.
    Wolff GL
    Fundam Appl Toxicol; 1996 Feb; 29(2):176-84. PubMed ID: 8742313
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential spontaneous transformation in vitro of newly established mouse fibroblast lines carrying or lacking the viable yellow mutation (Avy) of the mouse agouti locus.
    Hsiao WL; Wolff GL; North BM; Ollmann MM; Barsh GS; Fan H
    Mol Carcinog; 1996 Jan; 15(1):70-80. PubMed ID: 8561869
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prenatal determination of obesity, tumor susceptibility, and coat color pattern in viable yellow (Avy/a) mice. The yellow mouse syndrome.
    Wolff GL; Roberts DW; Galbraith DB
    J Hered; 1986; 77(3):151-8. PubMed ID: 3734404
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multiple levels of response in carcinogenicity bioassays: regulational variation among viable yellow (Avy/-) mice.
    Wolff GL
    J Exp Anim Sci; 1993 Sep; 35(5-6):221-31. PubMed ID: 8218437
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dose-response effects of ectopic agouti protein on iron overload and age-associated aspects of the Avy/a obese mouse phenome.
    Wolff GL; Whittaker P
    Peptides; 2005 Oct; 26(10):1697-711. PubMed ID: 15982784
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Suppression of in vitro chemical transformation by the carcinogenesis-promoting, viable yellow gene Avy.
    Furst AS; Becker FF
    Carcinogenesis; 1991 Jul; 12(7):1157-60. PubMed ID: 2070479
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential expression of a new dominant agouti allele (Aiapy) is correlated with methylation state and is influenced by parental lineage.
    Michaud EJ; van Vugt MJ; Bultman SJ; Sweet HO; Davisson MT; Woychik RP
    Genes Dev; 1994 Jun; 8(12):1463-72. PubMed ID: 7926745
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Liver-specific expression of the agouti gene in transgenic mice promotes liver carcinogenesis in the absence of obesity and diabetes.
    Kuklin AI; Mynatt RL; Klebig ML; Kiefer LL; Wilkison WO; Woychik RP; Michaud EJ
    Mol Cancer; 2004 Jun; 3():17. PubMed ID: 15175105
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular aspects of chemical carcinogenesis: the roles of oncogenes and tumour suppressor genes.
    Stanley LA
    Toxicology; 1995 Feb; 96(3):173-94. PubMed ID: 7900159
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Maternal epigenetics and methyl supplements affect agouti gene expression in Avy/a mice.
    Wolff GL; Kodell RL; Moore SR; Cooney CA
    FASEB J; 1998 Aug; 12(11):949-57. PubMed ID: 9707167
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Progression of tumor histiotype during mouse hepatocarcinogenesis associated with the viable yellow (Avy) gene.
    Becker FF
    Cancer Res; 1986 May; 46(5):2241-4. PubMed ID: 2421874
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Carcinogenic chemical-response "fingerprint" for male F344 rats exposed to a series of 195 chemicals: implications for predicting carcinogens with transgenic models.
    Johnson FM
    Environ Mol Mutagen; 1999; 34(4):234-45. PubMed ID: 10618171
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Supplement to the Carcinogenic Potency Database (CPDB): results of animal bioassays published in the general literature in 1993 to 1994 and by the National Toxicology Program in 1995 to 1996.
    Gold LS; Manley NB; Slone TH; Rohrbach L
    Environ Health Perspect; 1999 Aug; 107 Suppl 4(Suppl 4):527-600. PubMed ID: 10421768
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of gene knockout mice in understanding the mechanisms of chemical toxicity and carcinogenesis.
    Gonzalez FJ; Kimura S
    Cancer Lett; 1999 Sep; 143(2):199-204. PubMed ID: 10503904
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Are tumor incidence rates from chronic bioassays telling us what we need to know about carcinogens?
    Gaylor DW
    Regul Toxicol Pharmacol; 2005 Mar; 41(2):128-33. PubMed ID: 15698536
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Amplified response to phenobarbital promotion of hepatotumorigenesis in obese yellow Avy/A (C3H x VY) F-1 hybrid mice.
    Wolff GL; Morrissey RL; Chen JJ
    Carcinogenesis; 1986 Nov; 7(11):1895-8. PubMed ID: 3769139
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ectopic expression of the agouti gene in transgenic mice causes obesity, features of type II diabetes, and yellow fur.
    Klebig ML; Wilkinson JE; Geisler JG; Woychik RP
    Proc Natl Acad Sci U S A; 1995 May; 92(11):4728-32. PubMed ID: 7761391
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The results of assays in Drosophila as indicators of exposure to carcinogens.
    Vogel EW; Graf U; Frei HJ; Nivard MM
    IARC Sci Publ; 1999; (146):427-70. PubMed ID: 10353398
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hypervariable yellow (Ahvy), a new murine agouti mutation: Ahvy displays the largest variation in coat color phenotypes of all known agouti alleles.
    Siracusa LD; Washburn LL; Swing DA; Argeson AC; Jenkins NA; Copeland NG
    J Hered; 1995; 86(2):121-8. PubMed ID: 7751596
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The molecular basis for dominant yellow agouti coat color mutations.
    Perry WL; Copeland NG; Jenkins NA
    Bioessays; 1994 Oct; 16(10):705-7. PubMed ID: 7980472
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.